Insider Selling: Phreesia, Inc. (NYSE:PHR) COO Sells 1,845 Shares of Stock

Phreesia, Inc. (NYSE:PHR) COO Evan Roberts sold 1,845 shares of the company’s stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $23.81, for a total transaction of $43,929.45. Following the completion of the transaction, the chief operating officer now owns 774,807 shares of the company’s stock, valued at $18,448,154.67. This trade represents a 0.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Evan Roberts also recently made the following trade(s):

• On Tuesday, April 8th, Evan Roberts sold 7,233 shares of Phreesia stock. The stock was sold at an average price of $23.85, for a total transaction of $172,507.05.
• On Tuesday, February 18th, Evan Roberts sold 3,519 shares of Phreesia stock. The stock was sold at an average price of $30.06, for a total value of $105,781.14.
• On Thursday, February 13th, Evan Roberts sold 16,005 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total value of $480,150.00.
• On Monday, January 27th, Evan Roberts sold 10,716 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total value of $294,475.68.
• On Tuesday, January 21st, Evan Roberts sold 12,749 shares of Phreesia stock. The stock was sold at an average price of $27.31, for a total transaction of $348,175.19.

Phreesia Stock Performance

PHR opened at $23.92 on Friday. The company’s 50 day moving average is $26.07 and its 200 day moving average is $24.29. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.41 billion, a price-to-earnings ratio of -16.27 and a beta of 0.82. Phreesia, Inc. has a 12-month low of $17.07 and a 12-month high of $30.53.

Institutional Investors Weigh In On Phreesia

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Invesco Ltd. grew its holdings in Phreesia by 0.9% during the fourth quarter. Invesco Ltd. now owns 40,249 shares of the company’s stock valued at $1,013,000 after purchasing an additional 357 shares during the period. NewEdge Advisors LLC grew its stake in shares of Phreesia by 12.1% during the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company’s stock valued at $107,000 after acquiring an additional 459 shares during the period. QRG Capital Management Inc. grew its stake in shares of Phreesia by 8.0% during the 1st quarter. QRG Capital Management Inc. now owns 11,118 shares of the company’s stock valued at $284,000 after acquiring an additional 827 shares during the period. Johnson Financial Group Inc. increased its holdings in Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company’s stock worth $28,000 after acquiring an additional 896 shares in the last quarter. Finally, R Squared Ltd bought a new stake in Phreesia during the 4th quarter worth approximately $30,000. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PHR has been the subject of a number of analyst reports. Citigroup raised their target price on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Needham & Company LLC reissued a “buy” rating and issued a $29.00 target price on shares of Phreesia in a research note on Thursday, March 13th. KeyCorp lowered their price target on Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Wednesday. Royal Bank of Canada upgraded shares of Phreesia from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Piper Sandler reiterated an “overweight” rating and set a $33.00 price target (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Twelve investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.